Richard Saul, Ph.D.

Director, CPTAC Antibody Characterization Laboratory, Frederick National Laboratory for Cancer Research

Richard Saul

Dr. Saul spent the first 14 years of his career in the clinical diagnostics arena where he was responsible for the research and development of more than 25 diagnostic products, with experience in all aspects of product development, including technology development, assay development using various detection technologies, systems development for both unit-dose devices and high throughput instruments, management of marketing and regulatory activities, and directing the technical and manufacturing support of finished products. In 1999 he co-founded Axo Diagnostics, LLC., a Maryland based company that offered unique and customized services to the bioscience and medical diagnostic community, including assisting companies in the areas of technology assessment, contract development of diagnostic assays and automated detection technologies, and scientific multimedia production, including video production. In 2003 he became a sub-contractor for SAIC (now Leidos Biomedical Research) focusing on developing automated proteomic technologies. In 2014, Dr. Saul joined Leidos full-time as a Clinical Project Manager in the Antibody Characterization Lab (ACL), assuming the director’s role in 2018. Dr. Saul obtained a Bachelor of Science degree from Hampden-Sydney College (Hampden-Sydney, VA), a Ph.D. degree in Biochemistry from Virginia Commonwealth University’s Medical College of Virginia (Richmond, VA), and spent 2 years in post-doctoral training in the Biochemistry department at the University of Texas Health Science Center at San Antonio.